Claudin18.2 in Advanced Gastric Cancer

Area of Science:

• Gastroenterology and Oncology
• Molecular Targeted Therapy

Background:

• Gastric cancer (GC) is a leading cause of cancer mortality globally.
• Previous treatments like trastuzumab and ramucirumab showed survival benefits in specific patient populations.
• Immune checkpoint inhibitors (ICIs) have emerged as a treatment option, with chemotherapy plus ICIs improving survival in HER2-negative GC.

Purpose of the Study:

• To review recent clinical trials on CLDN18.2-targeted therapy for gastric cancer.
• To highlight the efficacy of zolbetuximab as a novel therapeutic agent.

Main Methods:

• Summary of findings from global phase III clinical trials.
• Focus on CLDN18.2-positive and HER2-negative gastric cancer patients.

Main Results:

• Zolbetuximab, a CLDN18.2-targeting monoclonal antibody, demonstrated efficacy in advanced GC.
• Addition of zolbetuximab to first-line chemotherapy significantly prolonged overall survival (OS) in CLDN18.2-positive, HER2-negative GC patients.

Conclusions:

• CLDN18.2-targeted therapy represents a significant advancement in gastric cancer treatment.
• Zolbetuximab shows potential for improving outcomes in a defined subset of GC patients.